RxDoctor Payments Data

Mary Merlo, APRN

Nurse Practitioner · Orland Park, ILNPI 1962892232

Payments from drug & device makers

$740in general payments, 2019–2025

Across 12 payments — averaging $61.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$272
  • Amgen$95
  • Ultragenyx Pharmaceutical Inc.$90
  • Lilly USA, LLC$85
  • Novo Nordisk$70
  • Phadia US Inc.$67
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences3$272
Amgen1$95
Ultragenyx Pharmaceutical Inc.1$90
Lilly USA, LLC1$85
Novo Nordisk1$70
Phadia US Inc.1$67
Alfasigma USA, Inc.1$18
GSK1$17
Boston Scientific1$14
AstraZeneca1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$740 in reported general payments places this provider in the 75th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$72,096
Medicare patients
408
Services billed
828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$34,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,407
Breo ElliptaFluticasone/Vilanterol19$16,954
OzempicSemaglutide16$16,814
MounjaroTirzepatide13$13,434
LinzessLinaclotide12$6,679
VascepaIcosapent Ethyl30$6,474
Levothyroxine Sodium460$3,741
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,579
Lubiprostone13$3,407
Atorvastatin Calcium347$2,883
Pantoprazole Sodium232$2,529
SynthroidLevothyroxine Sodium45$2,448
Bethanechol Chloride31$1,702
Albuterol Sulfate HfaAlbuterol Sulfate50$1,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$17$43,36148 claims
Novo NordiskOzempic$70$16,81416 claims
Lilly USA, LLCMounjaro$85$13,43413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →